{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:49:11Z","timestamp":1791931751046,"version":"4.3.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.eprac.2026.02.002","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:47:26Z","timestamp":1770943646000},"page":"962-971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and Efficacy of Oral PCSK9 Inhibitors in Hypercholesterolemia: A Systematic Review and Network Meta-Analysis"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5681-6522","authenticated-orcid":false,"given":"A.B.M.","family":"Kamrul-Hasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Nafis","family":"Shahriar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Nagendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deep","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Pappachan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.eprac.2026.02.002_bib1","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","article-title":"Global effect of modifiable risk factors on cardiovascular disease and mortality","volume":"389","author":"Magnussen","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2026.02.002_bib2","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s41043-025-01054-3","article-title":"Global prevalence of dyslipidemias in the general adult population: a systematic review and meta-analysis","volume":"44","author":"Ballena-Caicedo","year":"2025","journal-title":"J Health Popul Nutr"},{"issue":"6 Pt 2","key":"10.1016\/j.eprac.2026.02.002_bib3","article-title":"A critical appraisal of lipid management in the post-statin era: Comparison on guidelines, therapeutic targets, and screening in a case-based framework of lipid management","volume":"4","author":"Spitz","year":"2025","journal-title":"JACC Adv"},{"issue":"1","key":"10.1016\/j.eprac.2026.02.002_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pcad.2015.04.004","article-title":"Proprotein Convertase Subtilisin\/Kexin type 9 (PCSK9) inhibition and the future of lipid lowering therapy","volume":"58","author":"Joseph","year":"2015","journal-title":"Prog Cardiovasc Dis"},{"issue":"4","key":"10.1016\/j.eprac.2026.02.002_bib5","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jacl.2017.04.120","article-title":"Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: results of a healthcare provider survey conducted by the National Lipid Association","volume":"11","author":"Cohen","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.eprac.2026.02.002_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11883-024-01199-2","article-title":"Oral PCSK9 inhibitors","volume":"26","author":"Agarwala","year":"2024","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"10.1016\/j.eprac.2026.02.002_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11883-025-01299-7","article-title":"Oral PCSK9 inhibitors: will they work?","volume":"27","author":"Tokg\u00f6zo\u011flu","year":"2025","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.eprac.2026.02.002_bib8","article-title":"Oral PCSK9 inhibitors as an emerging frontier in lipid management: a meta-analysis","author":"Ho","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.eprac.2026.02.002_bib9","article-title":"Lipid-lowering efficacy and safety of oral proprotein convertase subtilisin\/kexin type 9 inhibitors: a systematic review and meta-analysis","author":"Masson","year":"2025","journal-title":"Adv Ther"},{"issue":"11","key":"10.1016\/j.eprac.2026.02.002_bib10","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.eprac.2026.02.002_bib11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12874-024-02356-6","article-title":"Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis","volume":"24","author":"Abbas","year":"2024","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.eprac.2026.02.002_bib12","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2026.02.002_bib13","series-title":"Review Manager (RevMan) [Computer program]","year":"2025"},{"key":"10.1016\/j.eprac.2026.02.002_bib14","series-title":"R: A language and environment for statistical computing","year":"2025"},{"key":"10.1016\/j.eprac.2026.02.002_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-2288-11-41","article-title":"Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics","volume":"11","author":"Bowden","year":"2011","journal-title":"BMC Med Res Methodol"},{"issue":"7414","key":"10.1016\/j.eprac.2026.02.002_bib16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.eprac.2026.02.002_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"issue":"16","key":"10.1016\/j.eprac.2026.02.002_bib18","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","article-title":"Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616","volume":"81","author":"Ballantyne","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.eprac.2026.02.002_bib19","article-title":"Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia: a randomized clinical trial","author":"Ballantyne","year":"2025","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.eprac.2026.02.002_bib20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S2213-8587(23)00325-X","article-title":"PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial","volume":"12","author":"Koren","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"21","key":"10.1016\/j.eprac.2026.02.002_bib21","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.jacc.2025.03.499","article-title":"An oral PCSK9 inhibitor for treatment of hypercholesterolemia: the PURSUIT randomized trial","volume":"85","author":"Koren","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.eprac.2026.02.002_bib22","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1161\/CIRCULATIONAHA.122.063372","article-title":"Orally bioavailable macrocyclic peptide that inhibits binding of PCSK9 to the low density lipoprotein receptor","volume":"148","author":"Johns","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.eprac.2026.02.002_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/circ.142.suppl_3.12579","article-title":"Abstract 12579: CVI-LM001, a first-in-class novel oral PCSK9 modulator, lowers plasma Ldl-c and reduces circulating PCSK9 in preclinical animal models and in hyperlipidemic human subjects","volume":"142","author":"Liu","year":"2020","journal-title":"Circulation"},{"issue":"Supplement 1","key":"10.1016\/j.eprac.2026.02.002_bib24","article-title":"AZD0780, the first oral small molecule PCSK9 inhibitor for the treatment of hypercholesterolemia: results from a randomized, single-blind, placebo-controlled phase 1 trial","volume":"295","author":"Vega","year":"2024","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.eprac.2026.02.002_bib25","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.cmet.2022.03.006","article-title":"Identification and evaluation of a lipid-lowering small compound in preclinical models and in a phase I trial","volume":"34","author":"Wang","year":"2022","journal-title":"Cell Metab"},{"issue":"10","key":"10.1016\/j.eprac.2026.02.002_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4100","article-title":"Publication and related biases","volume":"4","author":"Song","year":"2000","journal-title":"Health Technol Assess"},{"issue":"2","key":"10.1016\/j.eprac.2026.02.002_bib27","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/cpt.1193","article-title":"Adverse events associated with PCSK9 inhibitors: a real-world experience","volume":"105","author":"G\u00fcrg\u00f6ze","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.eprac.2026.02.002_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-26495-y","article-title":"Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes - exploratory analysis of the EMSIACS trial","volume":"15","author":"Jing","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.eprac.2026.02.002_bib29","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fphar.2020.00524","article-title":"Advances in oral drug delivery for regional targeting in the gastrointestinal tract - influence of physiological, pathophysiological and pharmaceutical factors","volume":"11","author":"Hua","year":"2020","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.eprac.2026.02.002_bib30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.eprac.2026.02.002_bib31","first-page":"e1046","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.eprac.2026.02.002_bib32","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.eprac.2026.02.002_bib33","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.eprac.2026.02.002_bib34","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.eprac.2026.02.002_bib35","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.eprac.2026.02.002_bib36","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2026.02.002_bib37","first-page":"49","article-title":"Angiopoietin-like protein 3 (ANGPTL3) inhibitors in the management of refractory hypercholesterolemia","volume":"14","author":"Kosmas","year":"2022","journal-title":"Clin Pharmacol"},{"issue":"14","key":"10.1016\/j.eprac.2026.02.002_bib38","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1080\/14656566.2024.2408369","article-title":"Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia","volume":"25","author":"Hooper","year":"2024","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"10.1016\/j.eprac.2026.02.002_bib39","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.eprac.2024.08.013","article-title":"Safety and efficacy of the novel RNA interference therapies for hypertriglyceridemia and mixed hyperlipidemia management: a systematic review and meta-analysis","volume":"30","author":"Kamrul-Hasan","year":"2024","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2026.02.002_bib40","article-title":"Treatment persistence, lipid lowering, and 3-year clinical outcomes in patients at very high cardiovascular risk on PCSK9 monoclonal antibodies","author":"Parhofer","year":"2025","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"10.1016\/j.eprac.2026.02.002_bib41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/CIRCULATIONAHA.124.068885","article-title":"Apolipoprotein B: Bridging the gap between evidence and clinical practice","volume":"150","author":"De Oliveira-Gomes","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.eprac.2026.02.002_bib42","doi-asserted-by":"crossref","DOI":"10.1177\/10742484231189597","article-title":"Residual atherosclerotic cardiovascular disease risk: focus on non-high-density lipoprotein cholesterol","volume":"28","author":"Luo","year":"2023","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.eprac.2026.02.002_bib43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40842-016-0024-x","article-title":"Lipoprotein (a), an independent cardiovascular risk marker","volume":"2","author":"Saeedi","year":"2016","journal-title":"Clin Diabetes Endocrinol"},{"issue":"24","key":"10.1016\/j.eprac.2026.02.002_bib44","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive Statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.eprac.2026.02.002_bib45","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26007779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26007779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:27:45Z","timestamp":1781018865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26007779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1530891X26007779"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.02.002","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Oral PCSK9 Inhibitors in Hypercholesterolemia: A Systematic Review and Network Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}